JNJ 55920839

Drug Profile

JNJ 55920839

Alternative Names: CNTO 6358

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Systemic lupus erythematosus in Belgium (IV) (NCT02609789)
  • 01 Dec 2015 Phase-I clinical trials in Systemic lupus erythematosus in Belgium (SC) (NCT02609789)
  • 24 Nov 2015 Janssen Research & Development plans a phase I trial for Systemic lupus erythematosus in Belgium (IV, SC) (NCT02609789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top